Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2011 (2011), Article ID 714978, 4 pages
Clinical Study

The Efficacy and Safety of Propiverine Hydrochloride in Patients with Overactive Bladder Symptoms Who Poorly Responded to Previous Anticholinergic Agents

1Department of Urology, Sapporo Medical University School of Medicine, Sapporo 060-8543, Japan
2Furuya Hospital, Urology service, Kitami 090-0065, Japan
3Iwasawa Clinic, Urology service, Sapporo 060-0061, Japan
4Nisshin Urological Clinic, Urology service, Tomakomai 053-0833, Japan
5NTT East Japan Sapporo Hospital, Division of Urology, Sapporo 060-0061, Japan
6Kaguraoka Urological Clinic, Urology service, Asahikawa 078-8315, Japan
7Kiyota Urological Clinic, Urology service, Sapporo 004-0841, Japan

Received 19 April 2011; Accepted 5 May 2011

Academic Editor: Yasuhiko Igawa

Copyright © 2011 Naoya Masumori et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objectives. To prospectively examine the efficacy and safety of propiverine hydrochloride in patients with overactive bladder (OAB) symptoms who poorly responded to previous treatment with solifenacin, tolterodine or imidafenacin. Methods. Patients aged ≥20 with persisting OAB symptoms (≥6 in OAB symptom score (OABSS)) even after at least 4-week treatment using solifenacin, tolterodine or imidafenacin were enrolled. Propiverine 20 mg/day was administered for 12 weeks to 70 patients who desired the further improvement of OAB symptoms and 3 who had intolerable adverse events of previous drugs. The OABSS and postvoid residual urine volume (PVR) were determined before and at 4 and 12 weeks of treatment. Results. Of 73 patients enrolled (29 males and 44 females, median age 71 years), 52 completed the protocol treatment. The OABSS was significantly improved by propiverine treatment (9.0 at baseline, 6.2 at 4 weeks, 6.3 at 12 weeks ( )). The scores of OAB symptoms (nighttime frequency, urgency and urge incontinence) except daytime frequency also improved significantly. No increase in PVR was observed. The most frequent adverse event was dry mouth (13.7%), followed by constipation (6.8%). Conclusions. Propiverine is useful to improve OAB for patients who poorly respond to solifenacin, tolterodine or imidafenacin.